Roisin Schimmel

Papers

2

Total Citations

346

H-Index

2

About

Roisin Schimmel is a leading clinical researcher in urologic oncology, with a primary focus on optimizing surgical outcomes for patients with bladder cancer. Her work centers on the comparative effectiveness and cost-efficiency of robot-assisted radical cystectomy (RARC) versus traditional open surgery. Schimmel’s landmark 2022 study, published in a top-tier journal, is a pivotal contribution to the field. Garnering over 320 citations, this randomized trial provided critical evidence on whether total intracorporeal robotic surgery improves 90-day morbidity and mortality compared to open radical cystectomy, directly addressing a key question in modern urology. Building on this, her 2023 cost-effectiveness analysis (26 citations) further clarified the value proposition of robotic surgery for healthcare payers, demonstrating a rigorous approach to evaluating both clinical and economic outcomes. By integrating high-level evidence on recovery, complications, and healthcare costs, Schimmel’s research helps guide surgical decision-making and policy in bladder cancer care. Her work is essential reading for surgeons, health economists, and trainees seeking to understand the real-world trade-offs of advanced surgical technologies.

Research Focus

Key Achievements

2
H-Index
2
Papers
346
Total Citations
173
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 70

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago